Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-01-05 DOI:10.1080/2162402x.2023.2300882

Carlo P. Ramil, Handan Xiang, Peng Zhang, Aileen Cronin, Lisia Cabral, Zhizhang Yin, Josephine Hai, Huijun Wang, Benjamin Ruprecht, Yanlin Jia, Dongyu Sun, Hongmin Chen, An Chi

引用次数: 0

查看原文本刊更多论文

癌症相关成纤维细胞诱导的髓源性抑制细胞释放的细胞外囊泡抑制 T 细胞功能

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.